Knight Therapeutics Enters Into Agreement for a $71 Million “Bought Deal” Private Placement of Special Warrants
MONTREAL, QUEBEC–(Marketwired – March 5, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) today announced that it has entered into a letter agreement with a […]
Knight Therapeutics Inc. Appoints New CFO
MONTREAL, CANADA–(Marketwired – Feb. 28, 2014) – Knight Therapeutics Inc. (TSX VENTURE:GUD) (“Knight”) announced today that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic […]
Knight Therapeutics Inc. to Begin Trading on March 3, 2014
MONTREAL, CANADA–(Marketwired – Feb. 28, 2014) – The Common Shares of Knight Therapeutics Inc. (TSX VENTURE:GUD) are now listed on the TSX Venture Exchange under the ticker symbol GUD and are expected to begin trading on March 3, 2014 at opening. Knight Therapeutics Inc. (“Knight”) is owned by the former shareholders of Paladin Labs Inc. […]